Eesti - eesti - Ravimiamet

abbvie sia - botulismitoksiin - süstelahuse pulber - 200ühik 6tk; 200ühik 3tk

Eesti - eesti - Ravimiamet

viatris healthcare limited - ibuprofeen - kihisevad graanulid - 400mg 12tk; 400mg 20tk; 400mg 30tk; 400mg 15tk; 400mg 40tk

Eesti - eesti - Ravimiamet

viatris healthcare limited - ibuprofeen - kihisevad graanulid - 200mg 20tk; 200mg 30tk; 200mg 12tk

Eesti - eesti - Ravimiamet

abbvie sia - botulismitoksiin - süstelahuse pulber - 100ühik 6tk; 100ühik 3tk; 100ühik 1tk

Eesti - eesti - Ravimiamet

abbvie sia - botulismitoksiin - süstelahuse pulber - 50ühik 10tk; 50ühik 6tk

Eesti - eesti - Ravimiamet

abbvie deutschland gmbh & co. kg - ombitasviir+paritapreviir+ritonaviir - õhukese polümeerikattega tablett - 12,5mg+75mg+50mg 64tk

Eesti - eesti - Ravimiamet

mylan ire healthcare limited - ibuprofeen - suukaudne suspensioon - 20mg 1ml 200ml 1tk; 20mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

abbvie deutschland gmbh & co. kg - dasabuviir - õhukese polümeerikattega tablett - 250mg 64tk

Eesti - eesti - Ravimiamet

abbvie s.r.l. - ademetioniin - tablett - 500mg 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.